Abstract:
INTRODUCTION AND AIM
The aim of our study is to compare patients monitored for ARDS diagnosis linked
to COVID-19 treated with spironolactone with patients who did not use
spironolactone and to retrospectively identify whether there was any positive
effect on mortality using clinical and laboratory data from patients.
MATERIAL AND METHOD
Two groups were created of patients treated due to severe ARDS diagnosis linked
to COVID-19. One group administered spironolactone (Group S, n=30) and the
other group was not (Group F, n=30). Groups were compared in terms of
demographic characteristics, presence of comorbidity, inotropic agent
requirements, (intensive care unit) ICU length of stay’, days of mechanical
ventilation and mortality. Additionally, fever, PO2/FIO2 (Horowitz ratio),
lymphocyte count, CRP value, SOFA scorer, and d-dimer levels on the ICU
length of stay, 1st day, 3rd day, 5th day, 8th day, 12th day, day of discharge or
day of exitus were compared between the groups and statistically analyzed.
RESULTS
Group S was found to have a higher ICU length of stay and days of mechanical
ventilation compared to Group F. (p<0.05). Group F had significantly a higher
mortality rate compared to Group S. (p<0.05). The final Horowitz value in Group
F was found to be significantly lower compared to Group S. (p<0.05). The
lymphocyte values in Group F were significantly lower than Group S on the 1st,
3rd, 5th, 8th and 12th day and at the final measurement. (p<0.05). The CRP values
in Group F were significantly higher than Group S on the 3rd, 5th, 8th and 12th
day and at the final measurement. (p<0.05). The SOFA scores on the 8th and
12th days and at the final measurement in Group F were found to be significantly
higher than GroupS. (p<0.05).
CONCLUSION
In our study, parameters for disease severity regressed, patients survived for
longer and mortality was identified to be lower in the group using spironolactone
